Profound Medical Corp. PROF
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -16.52%
- 1 year
- +7.35%
- Open
- 5.98
- Prev close
- 5.86
- Mkt cap
- 240.02M
- Vol
- 475.51K
- Avg vol
- 185.65K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.88
- High
- 6.63
- Forward P/E
- -7.95
- Beta
- 0.83
- Short ratio
- 7.87
- Inst. own
- 35.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.73
- 200-d avg
- 8.29
- 1y target
- 15.30
News
1 day ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
1 day ago zacks.com
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable,…
-
1 day ago benzinga.com
Profound Medical Strikes Supply, Distribution Deal With iMRI Division Of Cook Medical To Expand Sales Of TULSA-PRO System In U.S.
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
1 day ago globenewswire.com
Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
1 week ago globenewswire.com
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and…
2 weeks ago zacks.com
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
2 weeks ago globenewswire.com
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI…
3 weeks ago zacks.com
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…
-
3 weeks ago benzinga.com
Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures,
3 weeks ago globenewswire.com
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement…
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
3 weeks ago benzinga.com
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
-
3 weeks ago benzinga.com
Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
3 weeks ago globenewswire.com
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding…
1 month ago globenewswire.com
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
-
2 months ago benzinga.com
Profound Medical Appoints Richard Fabian As President, Effective Immediately, Succeeding Mathieu Burtnyk
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
2 months ago globenewswire.com
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
2 months ago globenewswire.com
Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers…
2 months ago globenewswire.com
Profound Medical Announces Management Change
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
2 months ago globenewswire.com
Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey
A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support
2 months ago marketbeat.com
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing…
2 months ago zacks.com
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.
-
2 months ago benzinga.com
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
-
2 months ago benzinga.com
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same…
2 months ago globenewswire.com
Profound Medical Reports Second Quarter 2026 Financial Results
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong…
3 months ago globenewswire.com
Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – – Whole-gland TULSA ablation demonstrates statistically…
3 months ago globenewswire.com
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
3 months ago globenewswire.com
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and…
3 months ago zacks.com
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength…
-
5 months ago benzinga.com
Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and…
-
5 months ago benzinga.com
Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate
Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of…
-
7 months ago benzinga.com
Profound Medical To Highlight Interventional MRI TULSA Procedure In Several Presentations At 2026 SIR Annual Scientific Meeting
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
7 months ago benzinga.com
Top 3 Health Care Stocks That Are Set To Fly In March
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.
-
7 months ago benzinga.com
Profound Medical Announces Level 1 Post-Market CAPTAIN Trial Comparing TULSA Procedure With Robotic RP Meets Primary Safety Endpoint In Grade Group 2 And 3 Prostate Cancer
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –– TULSA…
7 months ago benzinga.com
Profound Medical Q4 Earnings Assessment
Profound Medical Q4 Earnings Assessment
8 months ago benzinga.com
Earnings Summary: Profound Medical Q4
Earnings Summary: Profound Medical Q4
-
8 months ago benzinga.com
Profound Medical Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $5.977M Miss $7.233M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 35 percent decrease over losses of…
8 months ago benzinga.com
Profound Medical's Earnings: A Preview
Profound Medical's Earnings: A Preview
-
9 months ago benzinga.com
Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual functionThe Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World…
-
9 months ago benzinga.com
Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12
Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raises the price target from $11 to $12.
-
9 months ago benzinga.com
Profound Medical Announces First Non‑Trial Prostate Cancer Patient Treated With TULSA‑PRO At Johns Hopkins
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
-
10 months ago benzinga.com
Profound Medical Prices $40M Common Stock Offering
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering…
-
11 months ago benzinga.com
Profound Medical To Launch TULSA-AI Volume Reduction Module For Optimizing Treatment Of Patients With Benign Prostatic Hyperplasia, Or Enlarged Prostate, At RSNA Meeting
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
-
11 months ago benzinga.com
Profound Medical Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.289M Beat $4.995M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 31.58 percent increase over losses of…
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
11 months ago benzinga.com
Profound Medical Signs Distribution, Supply Agreement For Its TULSA-PRO System With Getz Healthcare In Australia, New Zealand
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free…
-
11 months ago benzinga.com
Profound Medical Enters Into Exclusive Distribution Agreement for TULSA-PRO And Sonalleve With Al Faisaliah Medical Systems In Saudi Arabia
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered, MRI-guided,…
-
11 months ago benzinga.com
Profound Medical Regains Exclusive Distribution Rights For TULSA-PRO From Knight Therapeutics In Canada
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered,…